China Pharma Proxy: 1:50 Reverse Split Vote and 8.03M-Share Equity Plan Increase
CPHI sits 44% above its 52-week low of $0.382.
Summary
China Pharma's definitive proxy asks holders to approve a reverse split of up to 1:50 to protect its NYSE American listing and to expand the 2010 incentive plan reserve by 8,034,200 shares — about 18.7% of the 43,022,002 shares outstanding if fully issued. The annual meeting is December 22, 2026.
Key Events · Corporate Governance and Compliance · CPHI
-
Reverse Split Up to 1:50 on Ballot
Proposal No. 2 authorizes the Board to effect a reverse stock split at a ratio of up to 1:50, at a time and ratio the Board chooses, to address NYSE American low-selling-price listing standards.
-
Equity Plan Reserve Jumps 8.03M Shares
Amendment No.4 would raise the 2010 Long-Term Incentive Plan reserve from 569,600 to 8,603,800 shares, an increase of 8,034,200 shares — roughly 18.7% of the 43,022,002 shares outstanding (8,034,200 / 43,022,002). No awards are contingent on approval.
-
Second Split Could Cost Cure Period
The company completed a 1-for-10 reverse split on April 15, 2025; a ratio above 1:20 before April 15, 2027 would bring the cumulative two-year ratio to 200:1 or more, exposing a future low-price deficiency to immediate suspension without a cure period.
-
Meeting Set for December 22, 2026
Record date is November 2, 2026, with 43,022,002 shares outstanding; holders also vote on re-electing independent directors Gene Michael Bennett, Yingwen Zhang and Baowen Dong.
Analysis · CPHI · Life Sciences
For a company trading at $0.551 with a roughly $23.7M market cap, two proposals carry real weight. The reverse split of up to 1:50 is a listing-defense measure: NYSE American can suspend or delist a stock that sells at a low price for a substantial period, and the proxy warns that failing to pass it could cost the listing. The equity plan amendment is the bigger dilution item. It would raise the reserve from 569,600 to 8,603,800 shares, an increase of 8,034,200 shares against 43,022,002 shares outstanding, so if fully granted and issued that is roughly 18.7% of today's share count (8,034,200 / 43,022,002). No awards have been granted contingent on approval, so this is authorization, not issuance. The split itself does not change ownership percentages, but the proxy flags that a ratio above 1:20 before April 15, 2027 would push the cumulative two-year split ratio to 200:1 or more, which under NYSE American rules removes any cure period on a future low-price deficiency. Shareholders vote December 22, 2026.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPHI was trading at $0.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $0.38 to $19.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.